Alnylam to advance zilebesiran into global phase 3 cardiovascular outcomes trial

Cambridge, mass.--(business wire)--alnylam pharmaceuticals, inc. (nasdaq: alny), the leading rnai therapeutics company, today announced plans to initiate a phase 3 cardiovascular outcomes trial (cvot) to evaluate the potential of zilebesiran to reduce the risk of major adverse cardiovascular events. this decision is informed by results from the comprehensive kardia phase 2 program, including kardia-3 results presented today as a late-breaking abstract at the european society of cardiology (esc).
ALNY Ratings Summary
ALNY Quant Ranking